Title: Prognostic Value of Plasma Level of Superoxide Dismutase in HBV-related Acute-on-
chronic Liver Failure
Version: 2 Date: 11 Apr 2022
Reviewer's report:
1. The authors have focused their analysis on 47 patients with HBV ACLF caused by
discontinuation of Entecavir. Please mention why Entecavir was discontinued in these 47
patients. What treatment was given to these patients ? Where they started on any anti-hepatitis
B medicines ?
2. Abstract. Increased plasma levels of HBV-DNA (4.79±0.14 vs 6.49±0.24, P<0.01)
Log10(HBV-DNA) and SOD (463.1±27.61 vs 397.2±10.97, P<0.05) were found in patients due
to ETV withdrawal. This line appears to be incorrect, as the HBV DNA level (4.79) mentioned
were lower in these patients.
3. Results: Sub Title 3.2: Withdrawal of ETV improved mortality rate in HBV ACLF patients.
This sub title / statement is incorrect, as mentioned in the first line in this section. (The mortality
rate of patients with HBV-ACLF was 46.71% in ETV group at 90 days, and 65.95% in ETV
withdrawal group.)
4. Plasm to be changed to Plasma, throughout the manuscript
5. Abbrevations : Lamivudine: LVD; Telbivudine: LDT are mentioned, however, these do not
appear in the manuscript.
Title: Prognostic Value of Plasma Level of Superoxide Dismutase in HBV-related Acute-on-
chronic Liver Failure
Version: 2 Date: 11 Apr 2022
Reviewer's report:
1. The authors have focused their analysis on 47 patients with HBV ACLF caused by
discontinuation of Entecavir. Please mention why Entecavir was discontinued in these 47
patients. What treatment was given to these patients ? Where they started on any anti-hepatitis
B medicines ?
2. Abstract. Increased plasma levels of HBV-DNA (4.79±0.14 vs 6.49±0.24, P<0.01)
Log10(HBV-DNA) and SOD (463.1±27.61 vs 397.2±10.97, P<0.05) were found in patients due
to ETV withdrawal. This line appears to be incorrect, as the HBV DNA level (4.79) mentioned
were lower in these patients.
3. Results: Sub Title 3.2: Withdrawal of ETV improved mortality rate in HBV ACLF patients.
This sub title / statement is incorrect, as mentioned in the first line in this section. (The mortality
rate of patients with HBV-ACLF was 46.71% in ETV group at 90 days, and 65.95% in ETV
withdrawal group.)
4. Plasm to be changed to Plasma, throughout the manuscript
5. Abbrevations : Lamivudine: LVD; Telbivudine: LDT are mentioned, however, these do not
appear in the manuscript.
Please review this paper.
user
Title: Prognostic Value of Plasma Level of Superoxide Dismutase in HBV-related Acute-on-
chronic Liver Failure
Version: 2 Date: 11 Apr 2022
Reviewer's report:
1. The authors have focused their analysis on 47 patients with HBV ACLF caused by
discontinuation of Entecavir. Please mention why Entecavir was discontinued in these 47
patients. What treatment was given to these patients ? Where they started on any anti-hepatitis
B medicines ?
2. Abstract. Increased plasma levels of HBV-DNA (4.79±0.14 vs 6.49±0.24, P<0.01)
Log10(HBV-DNA) and SOD (463.1±27.61 vs 397.2±10.97, P<0.05) were found in patients due
to ETV withdrawal. This line appears to be incorrect, as the HBV DNA level (4.79) mentioned
were lower in these patients.
3. Results: Sub Title 3.2: Withdrawal of ETV improved mortality rate in HBV ACLF patients.
This sub title / statement is incorrect, as mentioned in the first line in this section. (The mortality
rate of patients with HBV-ACLF was 46.71% in ETV group at 90 days, and 65.95% in ETV
withdrawal group.)
4. Plasm to be changed to Plasma, throughout the manuscript
5. Abbrevations : Lamivudine: LVD; Telbivudine: LDT are mentioned, however, these do not
appear in the manuscript.
assistant